HONG KONG, March 1 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com.
Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.
World Street Fundamentals has highlighted Dendreon for its lead product, Provenge (sipuleucel-T). The vaccine is designed to target a prostate cancer that is expressed in more than 90 % of all prostate cancers. Once known as one of the riskiest plays in the pharmaceutical world, Dendreon is now reaping the rewards of millions invested in the infrastructure for Provenge before FDA approval was granted. Recent setbacks for competitor AstraZeneca (NYSE: AZN) and its discontinuation of a phase III study on zibotentan, is also more good news for Dendreon's Provenge. To read the report on Dendreon Corp. (NASDAQ: DNDN), visit www.WorldStreetFundamentals.com.
Human Genome Sciences was another big mover in 2009 when it announced it reached successful endpoints in both of its Benlysta Phase III studies. Benlysta is an experimental drug for the treatment of lupus, an autoimmune disease in which the body's immune system attacks its own tissues. An estimated 322,000 Americans had systemic lupus erythematosus, the most common form and the one for which Benlysta may be approved.
To view fundamental and technical analysis on these two growing industry members we encourage investors to visit: www.WorldStreetFundamentals.com.
About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world. Covering the top performers in the hottest sectors and providing clarity to investors around the world.
FOR INFORMATIONAL PURPOSES ONLY, NO RECOMMENDATION TO BUY OR SELL SECURITIES SHOULD BE CONSTRUED FROM THIS RELEASE. WORLD STREET HAS NO RELATIONSHIP WITH THE ABOVE MENTIONED COMPANIES AND HAS NOT BEEN COMPENSATED BY ANY THIRD-PARTY.
SOURCE World Street Fundamentals